Collectively, our data illustrates that overactivation of AKT-signaling pathway in STS and GIST might serve as a prospective molecular target to enhance cytotoxicity of DNA-topoisomerase II inhibitors against STS and GIST. The gene discussed is AKT1; the disease is gastrointestinal stromal tumor.